Johnson & Johnson (JNJ) Offering Possible 11.11% Return Over the Next 37 Calendar Days

Johnson & Johnson’s most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $150.00 short put and a strike $140.00 long put offers a potential 11.11% return on risk over the next 37 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $150.00 by expiration. The full premium credit of $1.00 would be kept by the premium seller. The risk of $9.00 would be incurred if the stock dropped below the $140.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.

The RSI indicator is at 67.66 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Johnson & Johnson

Johnson & Johnson (JNJ) Stock Moves -0.42%: What You Should Know
Mon, 11 Jan 2021 22:45:10 +0000
In the latest trading session, Johnson & Johnson (JNJ) closed at $159.37, marking a -0.42% move from the previous day.

Dow snaps 4-day win streak as investors focus on hopes for recovery, political transition
Mon, 11 Jan 2021 21:42:00 +0000
U.S. stocks booked modest losses Monday, but were still near record territory, as investors focused on the prospects for economic recovery under the incoming Biden administration.

BioNTech Surges On Its Plan To Make 2 Billion Covid Vaccine Doses In 2021
Mon, 11 Jan 2021 21:34:50 +0000
BioNTech stock jumped Monday after the company said it plans to make 2 billion doses of its Pfizer-partnered coronavirus vaccine in 2021. J&J is reportedly aiming for 1 billion doses.

BioNTech CEO Says a Version of Its Covid Vaccine With Less Stringent Storage Requirements Could Come This Year
Mon, 11 Jan 2021 17:29:00 +0000
The (BNTX) the German biotech that worked with (PFE)to develop the first Covid-19 vaccine authorized by the U.S. Food and Drug Administration late last year, said Monday that the company was developing a thermostable version of its vaccine that could be available in the second half of the year. The extreme storage requirements of the company’s vaccine, which is shipped at -70° Celsius and can survive at temperatures of between 2° and 8° Celsius for only five days, have enormously complicated the distribution of the vaccine. Speaking at J.P. Morgan’s annual health-care conference, held remotely over videoconference this year, BioNTech’s (ticker: BNTX) CEO, Ugur Sahin, said that the company was working to fix that problem.

Futures Down as Investors Weigh Covid-19 Cases Against Vaccines
Mon, 11 Jan 2021 15:54:03 +0000
Futures Down as Investors Weigh Covid-19 Cases Against Vaccines

Be Sociable, Share!

Related Posts